

# Chapter 193

## Herpes Simplex

Adriana R. Marques & Jeffrey I. Cohen

### REFERENCES

1. Spruance SL et al: The natural history of recurrent herpes simplex labialis: Implications for antiviral therapy. *N Engl J Med* **297**(2):69-75, 1977
2. Schillinger JA et al: National seroprevalence and trends in herpes simplex virus type 1 in the United States, 1976–1994. *Sex Transm Dis* **31**(12):753-760, 2004
3. Embil JA, Stephens RG, Manuel FR: Prevalence of recurrent herpes labialis and aphthous ulcers among young adults on six continents. *Can Med Assoc J* **113**(7):627-630, 1975
4. Lafferty WE et al: Recurrences after oral and genital herpes simplex virus infection. Influence of site of infection and viral type. *N Engl J Med* **316**(23):1444-1449, 1987
5. Fleming DT et al: Herpes simplex virus type 2 in the United States, 1976 to 1994. *N Engl J Med* **337**(16):1105-1111, 1997
6. Xu F et al: Trends in herpes simplex virus type 1 and type 2 seroprevalence in the United States. *JAMA* **296**(8):964-973, 2006
7. Wald A et al: Reactivation of genital herpes simplex virus type 2 infection in asymptomatic seropositive persons. *N Engl J Med* **342**(12):844-850, 2000
8. Mark KE et al: Rapidly cleared episodes of herpes simplex virus reactivation in immunocompetent adults. *J Infect Dis* **198**(8):1141-1149, 2008
9. Kim HN et al: Does frequency of genital herpes recurrences predict risk of transmission? Further analysis of the valacyclovir transmission study. *Sex Transm Dis* **35**(2):124-128, 2008
10. Mertz GJ et al: Risk factors for the sexual transmission of genital herpes. *Ann Intern Med* **116**(3):197-202, 1992
11. Corey L et al: Once-daily valacyclovir to reduce the risk of transmission of genital herpes. *N Engl J Med* **350**(1):11-20, 2004
12. Langenberg AG et al: A prospective study of new infections with herpes simplex virus type 1 and type 2. Chiron HSV Vaccine Study Group. *N Engl J Med* **341**(19):1432-1438, 1999
13. Celum C et al: Effect of aciclovir on HIV-1 acquisition in herpes simplex virus 2 seropositive women and men who have sex with men: A randomised, double-blind, placebo-controlled trial. *Lancet* **371**(9630):2109-2119, 2008
14. Watson-Jones D et al: Effect of herpes simplex suppression on incidence of HIV among women in Tanzania. *N Engl J Med* **358**(15):1560-1571, 2008
15. McGeoch DJ, Cook S: Molecular phylogeny of the alphaherpesvirinae subfamily and a proposed evolutionary timescale. *J Mol Biol* **238**(1):9-22, 1994
16. Lekstrom-Himes JA, Pesnicak L, Straus SE: The quantity of latent viral DNA correlates with the relative rates at which herpes simplex virus types 1 and 2 cause recurrent genital herpes outbreaks. *J Virol* **72**(4):2760-2764, 1998
17. Bochud PY et al: Polymorphisms in TLR2 are associated with increased viral shedding and lesion rate in patients with genital herpes simplex virus Type 2 infection. *J Infect Dis* **196**(4):505-509, 2007
18. Khanna KM et al: Immune control of herpes simplex virus during latency. *Curr Opin Immunol* **16**(4):463-469, 2004
19. Verjans GM et al: Selective retention of herpes simplex virus-specific T cells in latently infected human trigeminal ganglia. *Proc Natl Acad Sci U S A* **104**(9):3496-3501, 2007
20. Zhu J et al: Virus-specific CD8+ T cells accumulate near sensory nerve endings in genital skin during subclinical HSV-2 reactivation. *J Exp Med* **204**(3):595-603, 2007
21. Young SK, Rowe NH, Buchanan RA: A clinical study for the control of facial mucocutaneous herpes virus infections. I. Characterization of natural history in a professional school population. *Oral Surg Oral Med Oral Pathol* **41**(4):498-507, 1976
22. Gupta R, Warren T, Wald A: Genital herpes. *Lancet* **370**(9605):2127-2137, 2007
23. Sucato G et al: Evidence of latency and reactivation of both herpes simplex virus (HSV)- 1 and HSV-2 in the genital region. *J Infect Dis* **177**(4):1069-1072, 1998

24. Johnston C et al: Herpes simplex virus viremia during primary genital infection. *J Infect Dis* **198**(1):31-34, 2008
25. Howell MD et al: Cathelicidin deficiency predisposes to eczema herpeticum. *J Allergy Clin Immunol* **117**(4):836-841, 2006
26. Slomka MJ et al: A comparison of PCR with virus isolation and direct antigen detection for diagnosis and typing of genital herpes. *J Med Virol* **55**(2):177-183, 1998
27. Groen J et al: Comparison of two enzyme-linked immunosorbent assays and one rapid immunoblot assay for detection of herpes simplex virus type 2-specific antibodies in serum. *J Clin Microbiol* **36**(3):845-847, 1998
28. Patel R: Supporting the patient with genital HSV infection. *Herpes* **11**(3):87-92, 2004
29. Ganatra JB et al: Viral causes of the acute retinal necrosis syndrome. *Am J Ophthalmol* **129**(2):166-172, 2000
30. Landry ML, Greenwold J, Vikram HR: Herpes simplex type-2 meningitis: Presentation and lack of standardized therapy. *Am J Med* **122**(7):688-691, 2009
31. Gilbert SC: Bell's palsy and herpesviruses. *Herpes* **9**(3):70-73, 2002
32. Whitley RJ, Gnann JW: The incidence and severity of herpes simplex encephalitis in Sweden, 1990–2001. *Clin Infect Dis* **45**(7):881-882, 2007
33. Hjalmarsson A, Blomqvist P, Skoldenberg B: Herpes simplex encephalitis in Sweden, 1990–2001: Incidence, morbidity, and mortality. *Clin Infect Dis* **45**(7):875-880, 2007
34. Corey L, Wald A: Maternal and neonatal herpes simplex virus infections. *N Engl J Med* **361**(14):1376-1385, 2009
35. Brown ZA et al: Effect of serologic status and cesarean delivery on transmission rates of herpes simplex virus from mother to infant. *JAMA* **289**(2):203-209, 2003
36. Brown ZA et al: The acquisition of herpes simplex virus during pregnancy. *N Engl J Med* **337**(8):509-515, 1997
37. Money D, Steben M: SOGC clinical practice guidelines: Guidelines for the management of herpes simplex virus in pregnancy. Number 208, June 2008. *Int J Gynaecol Obstet* **104**(2):167-171, 2009
38. ACOG Practice Bulletin: Clinical management guidelines for obstetrician-gynecologists. No. 82 June 2007. Management of herpes in pregnancy. *Obstet Gynecol* **109**(6):1489-1498, 2007
39. Sacks SL et al: Clinical efficacy of topical docosanol 10% cream for herpes simplex labialis: A multicenter, randomized, placebo-controlled trial. *J Am Acad Dermatol* **45**(2):222-230, 2001
40. Amir J et al: Treatment of herpes simplex gingivostomatitis with aciclovir in children: A randomised double blind placebo controlled study. *BMJ* **314**(7097):1800-1803, 1997
41. Boon R et al: Penciclovir cream for the treatment of sunlight-induced herpes simplex labialis: A randomized, double-blind, placebo-controlled trial. Penciclovir Cream Herpes Labialis Study Group. *Clin Ther* **22**(1):76-90, 2000
42. Spruance SL et al: Treatment of recurrent herpes simplex labialis with oral acyclovir. *J Infect Dis* **161**(2):185-190, 1990
43. Spruance SL et al: Peroral famciclovir in the treatment of experimental ultraviolet radiation-induced herpes simplex labialis: A double-blind, dose-ranging, placebo-controlled, multicenter trial. *J Infect Dis* **179**(2):303-310, 1999
44. Romanowski B et al: Efficacy and safety of famciclovir for treating mucocutaneous herpes simplex infection in HIV-infected individuals. Collaborative Famciclovir HIV Study Group. *Aids* **14**(9):1211-1217, 2000
45. Spruance SL et al: High-dose, short-duration, early valacyclovir therapy for episodic treatment of cold sores: Results of two randomized, placebo-controlled, multicenter studies. *Antimicrob Agents Chemother* **47**(3):1072-1080, 2003
46. Spruance SL et al: Single-dose, patient-initiated famciclovir: A randomized, double-blind, placebo-controlled trial for episodic treatment of herpes labialis. *J Am Acad Dermatol* **55**(1):47-53, 2006
47. Spruance SL et al: Acyclovir prevents reactivation of herpes simplex labialis in skiers. *JAMA* **260**(11):1597-1599, 1988
48. Rooney JF et al: Oral acyclovir to suppress frequently recurrent herpes labialis. A double-blind, placebo-controlled trial. *Ann Intern Med* **118**(4):268-272, 1993
49. Baker D, Eisen D: Valacyclovir for prevention of recurrent herpes labialis: 2 double-blind, placebo-controlled studies. *Cutis* **71**(3):239-242, 2003
50. Gilbert SC: Suppressive therapy versus episodic therapy with oral valacyclovir for recurrent herpes labialis: Efficacy and tolerability in an open-label, crossover study. *J Drugs Dermatol* **6**(4):400-405, 2007

51. Mertz GJ et al: Double-blind placebo-controlled trial of oral acyclovir in first- episode genital herpes simplex virus infection. *JAMA* 252(9):1147-1151, 1984
52. Fife KH et al: Valaciclovir versus acyclovir in the treatment of first-episode genital herpes infection. Results of an international, multicenter, double- blind, randomized clinical trial. The Valaciclovir International Herpes Simplex Virus Study Group. *Sex Transm Dis* 24(8):481-486, 1997
53. Antiviral Drugs. In: *Red Book: 2009 Report of the Committee on Infectious Diseases*, 28th edition, edited by LK Pickering, CJ Baker, DW Kimberlin, SS Long. Elk Grove Village, IL, American Academy of Pediatrics, 2009
54. Tyring SK et al: A randomized, placebo-controlled comparison of oval valacyclovir and acyclovir in immunocompetent patients with recurrent genital herpes infections. The Valaciclovir International Study Group. *Arch Dermatol* 134(2):185-191, 1998
55. Goldberg LH et al: Episodic twice-daily treatment for recurrent genital herpes. *Am J Med* 85(2A):10-13, 1988
56. Bodsworth NJ et al: Valaciclovir versus aciclovir in patient initiated treatment of recurrent genital herpes: A randomised, double blind clinical trial. International Valaciclovir HSV Study Group. *Genitourin Med* 73(2):110-116, 1997
57. Abudalu M et al: Single-day, patient-initiated famciclovir therapy versus 3-day valacyclovir regimen for recurrent genital herpes: A randomized, double-blind, comparative trial. *Clin Infect Dis* 47(5):651-658, 2008
58. Saiag P, Praindhui D, Chastang C: A double-blind, randomized study assessing the equivalence of valacyclovir 1000 mg once daily versus 500 mg twice daily in the episodic treatment of recurrent genital herpes. Genival Study Group. *J Antimicrob Chemother* 44(4):525-531, 1999
59. Bodsworth N et al: Single-day famciclovir for the treatment of genital herpes: Follow-up results of time to next recurrence and assessment of antiviral resistance. *Curr Med Res Opin* 25(2):483-487, 2009
60. Warren T, Harris J, Brennan CA: Efficacy and safety of valacyclovir for the suppression and episodic treatment of herpes simplex virus in patients with HIV. *Clin Infect Dis* 39(Suppl 5):S258-S266, 2004
61. Conant MA et al: Valaciclovir versus aciclovir for herpes simplex virus infection in HIV-infected individuals: Two randomized trials. *Int J STD AIDS* 13(1):12-21, 2002
62. Sacks SL et al: Clinic-initiated, twice-daily oral famciclovir for treatment of recurrent genital herpes: A randomized, double-blind, controlled trial. *Clin Infect Dis* 41(8):1097-1104, 2005
63. Bodsworth N et al: 2-day versus 5-day famciclovir as treatment of recurrences of genital herpes: Results of the FaST study. *Sex Health* 5(3):219-225, 2008
64. Aoki FY et al: Single-day, patient-initiated famciclovir therapy for recurrent genital herpes: A randomized, double-blind, placebo-controlled trial. *Clin Infect Dis* 42(1):8-13, 2006
65. Reitano M et al: Valaciclovir for the suppression of recurrent genital herpes simplex virus infection: A large-scale dose range-finding study. International Valaciclovir HSV Study Group. *J Infect Dis* 178(3):603-610, 1998
66. Mostow SR et al: Suppression of recurrent genital herpes by single daily dosages of acyclovir. *Am J Med* 85(2A):30-33, 1988
67. Wald A et al: Comparative efficacy of famciclovir and valacyclovir for suppression of recurrent genital herpes and viral shedding. *Sex Transm Dis* 33(9):529-533, 2006
68. Patel R et al: Valaciclovir for the suppression of recurrent genital HSV infection: A placebo controlled study of once daily therapy. International Valaciclovir HSV Study Group. *Genitourin Med* 73(2):105-109, 1997
69. Handsfield HH et al: Suppressive therapy with valacyclovir in early genital herpes: A pilot study of clinical efficacy and herpes-related quality of life. *Sex Transm Dis* 34(6):339-343, 2007
70. Fife KH et al: An international, randomized, double-blind, placebo-controlled, study of valacyclovir for the suppression of herpes simplex virus type 2 genital herpes in newly diagnosed patients. *Sex Transm Dis* 35(7):668-673, 2008
71. Bartlett BL et al: Famciclovir treatment options for patients with frequent outbreaks of recurrent genital herpes: The RELIEF trial. *J Clin Virol* 43(2):190-195, 2008
72. Tyring SK et al: Oral famciclovir for the suppression of recurrent genital herpes: The combined data from two randomized controlled trials. *J Cutan Med Surg* 7(6):449-454, 2003
73. Mertz GJ et al: Oral famciclovir for suppression of recurrent genital herpes simplex virus infection in women. A multicenter, double-blind, placebo- controlled trial. Collaborative Famciclovir Genital Herpes Research Group. *Arch Intern Med* 157(3):343-349, 1997

74. Sacks SL: Famciclovir suppression of asymptomatic and symptomatic recurrent anogenital herpes simplex virus shedding in women: A randomized, double-blind, double-dummy, placebo-controlled, parallel-group, single-center trial. *J Infect Dis* **189**(8):1341-1347, 2004
75. Watts DH et al: A double-blind, randomized, placebo-controlled trial of acyclovir in late pregnancy for the reduction of herpes simplex virus shedding and cesarean delivery. *Am J Obstet Gynecol* **188**(3):836-843, 2003
76. Scott LL et al: Acyclovir suppression to prevent recurrent genital herpes at delivery. *Infect Dis Obstet Gynecol* **10**(2):71-77, 2002
77. Sheffield JS et al: Valacyclovir prophylaxis to prevent recurrent herpes at delivery: A randomized clinical trial. *Obstet Gynecol* **108**(1):141-147, 2006
78. Andrews WW et al: Valacyclovir therapy to reduce recurrent genital herpes in pregnant women. *Am J Obstet Gynecol* **194**(3):774-781, 2006
79. Sozen E, Avunduk AM, Akyol N: Comparison of efficacy of oral valacyclovir and topical acyclovir in the treatment of herpes simplex keratitis: A randomized clinical trial. *Chemotherapy* **52**(1):29-31, 2006
80. Wilhelmus KR: Therapeutic interventions for herpes simplex virus epithelial keratitis. *Cochrane Database Syst Rev* (1):CD002898, 2008
81. Miserocchi E et al: Efficacy of valacyclovir vs acyclovir for the prevention of recurrent herpes simplex virus eye disease: A pilot study. *Am J Ophthalmol* **144**(4):547-551, 2007
82. Wilhelmus KR et al: Acyclovir for the prevention of recurrent herpes simplex virus eye disease. Herpetic Eye Disease Study Group. *N Engl J Med* **339**(5):300-306, 1998
83. Kimberlin DW et al: Safety and efficacy of high-dose intravenous acyclovir in the management of neonatal herpes simplex virus infections. *Pediatrics* **108**(2):230-238, 2001
84. Cernik C, Gallina K, Brodell RT: The treatment of herpes simplex infections: An evidence-based review. *Arch Intern Med* **168**(11):1137-1144, 2008
85. Leone P et al: One-day famciclovir vs. placebo in patient-initiated episodic treatment of recurrent genital herpes in immunocompetent Black patients. *Curr Med Res Opin* **26**(3):653-661, 2010
86. Straus SE et al: Acyclovir suppression of frequently recurring genital herpes. Efficacy and diminishing need during successive years of treatment. *JAMA* **260**(15):2227-2230, 1988
87. Diaz-Mitoma F et al: Oral famciclovir for the suppression of recurrent genital herpes: A randomized controlled trial. Collaborative Famciclovir Genital Herpes Research Group. *JAMA* **280**(10):887-892, 1998
88. Fife KH et al: Effect of valacyclovir on viral shedding in immunocompetent patients with recurrent herpes simplex virus 2 genital herpes: A US-based randomized, double-blind, placebo-controlled clinical trial. *Mayo Clin Proc* **81**(10):1321-1327, 2006
89. DeJesus E et al: Valacyclovir for the suppression of recurrent genital herpes in human immunodeficiency virus-infected subjects. *J Infect Dis* **188**(7):1009-1016, 2003
90. Fife KH, Almekinder J, Ofner S: A comparison of one year of episodic or suppressive treatment of recurrent genital herpes with valacyclovir. *Sex Transm Dis* **34**(5):297-301, 2007
91. Hollier LM, Wendel GD: Third trimester antiviral prophylaxis for preventing maternal genital herpes simplex virus (HSV) recurrences and neonatal infection. *Cochrane Database Syst Rev* (1):CD004946, 2008
92. Raborn GW et al: Oral acyclovir in prevention of herpes labialis. A randomized, double-blind, multi-centered clinical trial. *Oral Surg Oral Med Oral Pathol Oral Radiol Endod* **85**(1):55-59, 1998
93. Wall SH, Ramey SJ, Wall F: Famciclovir as antiviral prophylaxis in laser resurfacing procedures. *Plast Reconstr Surg* **104**(4):1103-1108, 1999; discussion 1109
94. Gilbert S, McBurney E. Use of valacyclovir for herpes simplex virus-1 (HSV-1) prophylaxis after facial resurfacing: A randomized clinical trial of dosing regimens. *Dermatol Surg* **26**(1):50-54, 2000
95. Anderson BJ: The effectiveness of valacyclovir in preventing reactivation of herpes gladiatorum in wrestlers. *Clin J Sport Med* **9**(2):86-90, 1999
96. Lalezari J et al: A randomized, double-blind, placebo-controlled trial of cidofovir gel for the treatment of acyclovir-unresponsive mucocutaneous herpes simplex virus infection in patients with AIDS. *J Infect Dis* **176**(4):892-898, 1997
97. Martinez V et al: Topical imiquimod for recurrent acyclovir-resistant HSV infection. *Am J Med* **119**(5):e9-e11, 2006
98. Bernstein DI et al: Evaluation of imiquimod 5% cream to modify the natural history of herpes labialis: A pilot study. *Clin Infect Dis* **41**(6):808-814, 2005

99. Mark KE et al: Topical resiquimod 0.01% gel decreases herpes simplex virus type 2 genital shedding: A randomized, controlled trial. *J Infect Dis* **195**(9):1324-1331, 2007
100. Fife KH et al: Effect of resiquimod 0.01% gel on lesion healing and viral shedding when applied to genital herpes lesions. *Antimicrob Agents Chemother* **52**(2):477-82, 2008
101. Erard V et al: Use of long-term suppressive acyclovir after hematopoietic stem-cell transplantation: Impact on herpes simplex virus (HSV) disease and drug-resistant HSV disease. *J Infect Dis* **196**(2):266-270, 2007
102. Martin ET et al: A pooled analysis of the effect of condoms in preventing HSV-2 acquisition. *Arch Intern Med* **169**(13):1233-1240, 2009
103. Tobian AA et al: Male circumcision for the prevention of HSV-2 and HPV infections and syphilis. *N Engl J Med* **360**(13):1298-1309, 2009
104. Sperling RS et al: The effect of daily valacyclovir suppression on herpes simplex virus type 2 viral shedding in HSV-2 seropositive subjects without a history of genital herpes. *Sex Transm Dis* **35**(3):286-290, 2008
105. Gupta R et al: Valacyclovir and acyclovir for suppression of shedding of herpes simplex virus in the genital tract. *J Infect Dis* **190**(8):1374-1381, 2004
106. Martens MG et al: Once daily valacyclovir for reducing viral shedding in subjects newly diagnosed with genital herpes. *Infect Dis Obstet Gynecol* **2009**:105376, 2009
107. Keller MJ et al: PRO 2000 gel inhibits HIV and herpes simplex virus infection following vaginal application: A double-blind placebo-controlled trial. *J Infect Dis* **193**(1):27-35, 2006
108. Straus SE et al: Immunotherapy of recurrent genital herpes with recombinant herpes simplex virus type 2 glycoproteins D and B: results of a placebo-controlled vaccine trial. *J Infect Dis* **176**(5):1129-1134, 1997
109. Corey L et al: Recombinant glycoprotein vaccine for the prevention of genital HSV-2 infection: Two randomized controlled trials. Chiron HSV Vaccine Study Group. *JAMA* **282**(4):331-340, 1999
110. Stanberry LR et al: Glycoprotein-D-adjuvant vaccine to prevent genital herpes. *N Engl J Med* **347**(21):1652-1661, 2002
111. de Bruyn G et al: A randomized controlled trial of a replication defective (gH deletion) herpes simplex virus vaccine for the treatment of recurrent genital herpes among immunocompetent subjects. *Vaccine* **24**(7):914-920, 2006
112. Cattamanchi A et al: Phase I study of a herpes simplex virus type 2 (HSV-2) DNA vaccine administered to healthy, HSV-2-seronegative adults by a needle-free injection system. *Clin Vaccine Immunol* **15**(11):1638-1643, 2008
113. Chosidow O et al: Famciclovir vs. aciclovir in immunocompetent patients with recurrent genital herpes infections: A parallel-groups, randomized, double-blind clinical trial. *Br J Dermatol* **144**(4):818-824, 2001

